A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Clinical trial NCT01691898 · COMPLETED

Trial details

NCT number: NCT01691898
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Follicular Lymphoma Diffuse Large B-Cell Lymphoma

Start date: 2012-09-27
Primary completion: 2017-03-08
Enrollment: 231

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.